Edgewise CBO granted 100K options at $43.56

Edgewise Therapeutics, Inc. reported that Chief Business Officer Behrad Derakhshan received a grant of 100,000 stock options to purchase common stock.

Rhea-AI Filing Summary

Edgewise Therapeutics, Inc. reported that Chief Business Officer Behrad Derakhshan received a grant of 100,000 stock options to purchase common stock. This amendment corrects the option’s exercise price to $43.56 per share, reflecting the fair market value on the grant date. The options vest in 1/48 monthly installments beginning September 12, 2026, contingent on continued service, and expire on August 12, 2036. Following this grant, Derakhshan holds 100,000 derivative securities directly.

Insider Trade Summary

Grant/Award: 100,000 shares

Grant/Award 1 txn

Insider Derakhshan Behrad

Role Chief Business Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	100,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 100,000 contracts (Direct)

Footnotes (1)

1. F1. 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.

Key Figures

Options Granted: 100,000 shares Exercise Price: $43.56 per share Underlying Shares: 100,000 shares +4 more

7 metrics

Options Granted 100,000 shares Stock Option (Right to Buy) granted to Chief Business Officer

Exercise Price $43.56 per share Corrected option exercise price reflecting fair market value on grant date

Underlying Shares 100,000 shares Common Stock underlying the reported stock option

Post-transaction Derivative Holdings 100,000 shares Total derivative securities held directly after the grant

Vesting Rate 1/48 per month Monthly vesting installments beginning September 12, 2026

Vesting Start Date September 12, 2026 First vesting date for the stock option grant

Expiration Date August 12, 2036 Option expiration for the stock option (right to buy)

Key Terms

Stock Option (Right to Buy), exercise price, vesting, derivative securities, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"corrects the exercise price of the reported option grant"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"1/48th of the shares subject to the option vest each month"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

derivative securities financial

"total_shares_following_transaction: 100000.0000 derivative securities"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

fair market value financial

"reflects the fair market value of the underlying security"

The price a willing buyer and a willing seller would agree on for an asset or security when neither is under pressure and both have access to the same information. Think of it as the market’s neutral estimate of what something is worth, like the price two neighbors would settle on for a car after comparing similar listings. Investors care because fair market value guides buying and selling decisions, tax reporting, portfolio valuation, and how accurately company assets are reflected in financial statements.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider equity award was reported for Edgewise Therapeutics (EWTX)?

Edgewise Therapeutics reported a grant of 100,000 stock options to Chief Business Officer Behrad Derakhshan. These options relate to the company’s common stock and represent a new equity-based compensation award.

What is the corrected exercise price of the EWTX stock options in this Form 4/A?

The amendment corrects the option exercise price to $43.56 per share. The original filing mistakenly showed $0.00 due to a clerical error; $43.56 reflects fair market value on the grant date.

How do the Edgewise Therapeutics (EWTX) options granted to Derakhshan vest?

The options vest in 1/48th of the shares each month starting September 12, 2026. Vesting is conditioned on Derakhshan continuing as a service provider through each monthly vesting date.

When do the reported Edgewise Therapeutics (EWTX) stock options expire?

The stock options expire on August 12, 2036. If unexercised by that date, the right to purchase the underlying common shares lapses according to the award’s stated expiration.

How many Edgewise Therapeutics (EWTX) derivative securities does Derakhshan hold after this grant?

After the reported grant, Derakhshan directly holds 100,000 derivative securities in the form of stock options. This figure reflects the total options position reported following the transaction.

Was the Edgewise Therapeutics (EWTX) option transaction under a Rule 10b5-1 plan?

The filing indicates the Rule 10b5-1 checkbox is not affirmatively marked for this transaction. There is no footnote stating that the grant occurred under a pre-arranged 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/17/2026 - 06:41 PM Accepted by SEC EDGAR 08/17/2026 - 06:39 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Derakhshan Behrad

(Last) (First) (Middle)

C/O EDGEWISE THERAPEUTICS, INC.

1715 38TH STREET

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
08/14/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$43.56	08/12/2026		A		100,000		(1)	08/12/2036	Common Stock	100,000	$0.00	100,000	D

Explanation of Responses:

1. 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.

Remarks:

This amendment corrects the exercise price of the reported option grant, which was reported as $0.00 due to a clerical/administrative error. The correct exercise price is $43.56, which reflects the fair market value of the underlying security on the date of grant.

	/s/ John R Moore Attorney-in-Fact for Behrad Derakhshan	08/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)